{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T22:22:21Z","timestamp":1746224541289},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s00595-010-4392-z","type":"journal-article","created":{"date-parts":[[2011,7,11]],"date-time":"2011-07-11T13:08:32Z","timestamp":1310389712000},"page":"1016-1019","source":"Crossref","is-referenced-by-count":8,"title":["De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: Report of a case"],"prefix":"10.1007","volume":"41","author":[{"given":"Kazuki","family":"Takeishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Shirabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Toshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoyo","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takasuke","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Motomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Mano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Soejima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Taketomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,7,12]]},"reference":[{"key":"4392_CR1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","volume":"122","author":"L.M. Forman","year":"2002","unstructured":"Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889\u2013896.","journal-title":"Gastroenterology"},{"key":"4392_CR2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00595-008-4024-z","volume":"39","author":"K. Hasegawa","year":"2009","unstructured":"Hasegawa K, Kokudo N. Surgical treatment of hepatocellular carcinoma. Surg Today 2009;39:833\u2013843.","journal-title":"Surg Today"},{"key":"4392_CR3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jhep.2003.12.015","volume":"40","author":"J. Dumortier","year":"2004","unstructured":"Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis after liver transplantation \u2014 a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004;40:669\u2013674.","journal-title":"J Hepatol"},{"key":"4392_CR4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","volume":"39","author":"D.B. Strader","year":"2004","unstructured":"Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147\u20131171.","journal-title":"Hepatology"},{"key":"4392_CR5","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","volume":"55","author":"M.P. Manns","year":"2006","unstructured":"Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006;55:1350\u20131359.","journal-title":"Gut"},{"key":"4392_CR6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/08916930310001602137","volume":"36","author":"B. Conrad","year":"2003","unstructured":"Conrad B. Potential mechanisms of interferon-alpha induced autoimmunity. Autoimmunity 2003;36:519\u2013523.","journal-title":"Autoimmunity"},{"key":"4392_CR7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/gut.2006.092064","volume":"56","author":"S. Berardi","year":"2007","unstructured":"Berardi S, Lodato F, Gramenzi A, D\u2019Errico A, Lenzi M, Bontadini A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon-alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007;56:237\u2013242.","journal-title":"Gut"},{"key":"4392_CR8","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.tp.0000196716.07188.c4","volume":"81","author":"E. Cholongitas","year":"2006","unstructured":"Cholongitas E, Samonakis D, Patch D, Senzolo M, Burroughs AK, Quaglia A, et al. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006;81:488\u2013490.","journal-title":"Transplantation"},{"key":"4392_CR9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/lt.20706","volume":"12","author":"N. Kontorinis","year":"2006","unstructured":"Kontorinis N, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl 2006;12:827\u2013830.","journal-title":"Liver Transpl"},{"key":"4392_CR10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.dld.2008.09.015","volume":"41","author":"M. Merli","year":"2009","unstructured":"Merli M, Gentili F, Giusto M, Attili AF, Corradini SG, Mennini G, et al. Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis? Dig Liver Dis 2009;41:345\u2013349.","journal-title":"Dig Liver Dis"},{"key":"4392_CR11","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1126\/science.3368786","volume":"240","author":"J.A. Todd","year":"1988","unstructured":"Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, Jacob CO, et al. A molecular basis for MHC class II-associated autoimmunity. Science 1988;240:1003\u20131009.","journal-title":"Science"},{"key":"4392_CR12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.autrev.2004.03.003","volume":"3","author":"Y. Oppenheim","year":"2004","unstructured":"Oppenheim Y, Ban Y, Tomer Y. Interferon induced autoimmune thyroid disease: a model for human autoimmunity. Autoimmunity Rev 2004;3:388\u2013393.","journal-title":"Autoimmunity Rev"},{"key":"4392_CR13","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archinte.158.13.1445","volume":"158","author":"L. Fernandez-Soto","year":"1998","unstructured":"Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs. hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 1998;158:1445\u20131448.","journal-title":"Arch Intern Med"},{"key":"4392_CR14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0301-472X(98)00051-4","volume":"27","author":"S. Brawn","year":"1999","unstructured":"Brawn S, Tare N, Inoue T, Yamasaki M, Okabe M, Horii I, et al. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp Hematol 1999;27:425\u2013432.","journal-title":"Exp Hematol"},{"key":"4392_CR15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jps.2600830432","volume":"83","author":"T. Yamaoka","year":"1994","unstructured":"Yamaoka T, Tabata Y, Ikeda Y. Distribution and tissue uptake of poly (ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 1994;83:601\u2013606.","journal-title":"J Pharm Sci"},{"key":"4392_CR16","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/gut.2005.083113","volume":"55","author":"M. Sherman","year":"2006","unstructured":"Sherman M, Yoshida EM, Deschenes M, Krajden M, Bain VG, Peltekian K, et al. Peginterferon alpha-2a (40 KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006;55:1631\u20131638.","journal-title":"Gut"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-010-4392-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00595-010-4392-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-010-4392-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T10:00:14Z","timestamp":1559124014000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00595-010-4392-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["4392"],"URL":"https:\/\/doi.org\/10.1007\/s00595-010-4392-z","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}